Changes in circulating microRNA levels associated with prostate cancer - PubMed (original) (raw)
Changes in circulating microRNA levels associated with prostate cancer
R J Bryant et al. Br J Cancer. 2012.
Abstract
Background: The aim of this study was to investigate the hypothesis that changes in circulating microRNAs (miRs) represent potentially useful biomarkers for the diagnosis, staging and prediction of outcome in prostate cancer.
Methods: Real-time polymerase chain reaction analysis of 742 miRs was performed using plasma-derived circulating microvesicles of 78 prostate cancer patients and 28 normal control individuals to identify differentially quantified miRs.
Results: A total of 12 miRs were differentially quantified in prostate cancer patients compared with controls, including 9 in patients without metastases. In all, 11 miRs were present in significantly greater amounts in prostate cancer patients with metastases compared with those without metastases. The association of miR-141 and miR-375 with metastatic prostate cancer was confirmed using serum-derived exosomes and microvesicles in a separate cohort of patients with recurrent or non-recurrent disease following radical prostatectomy. An analysis of five selected miRs in urine samples found that miR-107 and miR-574-3p were quantified at significantly higher concentrations in the urine of men with prostate cancer compared with controls.
Conclusion: These observations suggest that changes in miR concentration in prostate cancer patients may be identified by analysing various body fluids. Moreover, circulating miRs may be used to diagnose and stage prostate cancer.
Conflict of interest statement
TP and BR are employed by Caris Life Sciences; RV has been recipient of a commercial research grant from Caris Life Sciences.
Figures
Figure 1
Overview of miR analysis of plasma, serum and urine samples.
Figure 2
Taqman qRT–PCR analysis using an independent University of Washington serum cohort of exosome fractions verified the quantification changes of miR-375 (A) and miR-141 (B) (_P_=0.0001 Mann–Whitney U test).
Figure 3
MicroRNAs-107 and 574-3p in urinary prostate cells are associated with the presence of cancer. (A) The quantity (shown as ΔCt values with respect to reference snoRNAs) is higher in prostate cancer cases, when compared with controls. (B) This quantification can be used to identify the presence of prostate cancer from urine samples (AUC ROC shown in brackets).
Similar articles
- Circulating microRNAs in plasma before and after radical prostatectomy.
McDonald AC, Raman JD, Shen J, Liao J, Pandya B, Vira MA. McDonald AC, et al. Urol Oncol. 2019 Nov;37(11):814.e1-814.e7. doi: 10.1016/j.urolonc.2019.07.001. Epub 2019 Aug 14. Urol Oncol. 2019. PMID: 31421994 Free PMC article. - Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
Zidan HE, Abdul-Maksoud RS, Elsayed WSH, Desoky EAM. Zidan HE, et al. IUBMB Life. 2018 May;70(5):437-444. doi: 10.1002/iub.1733. Epub 2018 Mar 9. IUBMB Life. 2018. PMID: 29522280 - Circulating miR-20a and miR-26a as Biomarkers in Prostate Cancer.
Mohammadi Torbati P, Asadi F, Fard-Esfahani P. Mohammadi Torbati P, et al. Asian Pac J Cancer Prev. 2019 May 25;20(5):1453-1456. doi: 10.31557/APJCP.2019.20.5.1453. Asian Pac J Cancer Prev. 2019. PMID: 31127907 Free PMC article. - The Functional Role of Prostate Cancer Metastasis-related Micro-RNAs.
Weidle UH, Epp A, Birzele F, Brinkmann U. Weidle UH, et al. Cancer Genomics Proteomics. 2019 Jan-Feb;16(1):1-19. doi: 10.21873/cgp.20108. Cancer Genomics Proteomics. 2019. PMID: 30587496 Free PMC article. Review. - Circulating microRNAs as potential new biomarkers for prostate cancer.
Sita-Lumsden A, Dart DA, Waxman J, Bevan CL. Sita-Lumsden A, et al. Br J Cancer. 2013 May 28;108(10):1925-30. doi: 10.1038/bjc.2013.192. Epub 2013 Apr 30. Br J Cancer. 2013. PMID: 23632485 Free PMC article. Review.
Cited by
- From microscopes to molecules: The evolution of prostate cancer diagnostics.
Tao J, Bian X, Zhou J, Zhang M. Tao J, et al. Cytojournal. 2024 Aug 29;21:29. doi: 10.25259/Cytojournal_36_2024. eCollection 2024. Cytojournal. 2024. PMID: 39391208 Free PMC article. Review. - Extracellular RNAs from Whole Urine to Distinguish Prostate Cancer from Benign Prostatic Hyperplasia.
Stella M, Russo GI, Leonardi R, Carcò D, Gattuso G, Falzone L, Ferrara C, Caponnetto A, Battaglia R, Libra M, Barbagallo D, Di Pietro C, Pernagallo S, Barbagallo C, Ragusa M. Stella M, et al. Int J Mol Sci. 2024 Sep 19;25(18):10079. doi: 10.3390/ijms251810079. Int J Mol Sci. 2024. PMID: 39337566 Free PMC article. - Current landscape of exosomal non-coding RNAs in prostate cancer: Modulators and biomarkers.
Li Y, Tang X, Wang B, Chen M, Zheng J, Chang K. Li Y, et al. Noncoding RNA Res. 2024 Jul 20;9(4):1351-1362. doi: 10.1016/j.ncrna.2024.07.003. eCollection 2024 Dec. Noncoding RNA Res. 2024. PMID: 39247145 Free PMC article. Review. - A Novel Liquid Biopsy Method Based on Specific Combinations of Vesicular Markers Allows Us to Discriminate Prostate Cancer from Hyperplasia.
Martorana E, Raciti G, Giuffrida R, Bruno E, Ficarra V, Ludovico GM, Suardi NR, Iraci N, Leggio L, Bussolati B, Grange C, Lorico A, Leonardi R, Forte S. Martorana E, et al. Cells. 2024 Jul 31;13(15):1286. doi: 10.3390/cells13151286. Cells. 2024. PMID: 39120316 Free PMC article. - Muscle-derived exosomes and exercise in cancer prevention.
Vitucci D, Martone D, Alfieri A, Buono P. Vitucci D, et al. Front Mol Med. 2023 Jun 6;3:1202190. doi: 10.3389/fmmed.2023.1202190. eCollection 2023. Front Mol Med. 2023. PMID: 39086668 Free PMC article. Review.
References
- Brase JC, Johannes M, Schlomm T, Falth M, Haese A, Steuber T, Beissbarth T, Kuner R, Sultmann H (2011) Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer 128: 608–616 - PubMed
- Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T, Visakorpi T (2011) MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol 59: 671–681 - PubMed
- Ciatto S, Zappa M, Bonardi R, Gervasi G (2000) Prostate cancer screening: the problem of overdiagnosis and lessons to be learned from breast cancer screening. Eur J Cancer 36: 1347–1350 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- CA-097186/CA/NCI NIH HHS/United States
- RG45910-GO900871/CRUK_/Cancer Research UK/United Kingdom
- P01 CA085859/CA/NCI NIH HHS/United States
- P01 CA-085859/CA/NCI NIH HHS/United States
- P50 CA097186/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical